Abstract:AAV‐based gene therapy are on increasing demand to cover the needs in the patient communities with inherited genetic disorders. Single AAV vectors delivering functional gene copy are the most popular approach in RnD pipeline. Multiple split vectors, inteins and trans‐splicing strategy so far underperform monovector AAV‐delivery. Neural networks guided by protein fitness data facilitate de novo protein design to fit into AAV capsid. Adeno‐associated virus (AAV)‐based therapies are recognized as one of the most potent next‐generation treatments for inherited and genetic diseases. However, several biological and technological aspects of AAV vectors remain a critical issue for their widespread clinical application. Among them, the limited capacity of the AAV genome significantly hinders the development of AAV‐based gene therapy. In this context, genetically modified transgenes compatible with AAV are opening up new opportunities for unlimited gene therapies for many genetic disorders. Recent advances in de novo protein design and remodelling are paving the way for new, more efficient and targeted gene therapeutics. Using computational and genetic tools, AAV expression cassette and transgenic DNA can be split, miniaturized, shuffled or created from scratch to mediate efficient gene transfer into targeted cells. In this review, we highlight recent advances in AAV‐based gene therapy with a focus on its use in translational research. We summarize recent research and development in gene therapy, with an emphasis on large transgenes (>4.8 kb) and optimizing strategies applied by biomedical companies in the research pipeline. We critically discuss the prospects for AAV‐based treatment and some emerging challenges. We anticipate that the continued development of novel computational tools will lead to rapid advances in basic gene therapy research and translational studies.

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges

AAV-based in vivo gene therapy for neurological disorders

Engineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system

Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases

Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases

Optimization strategies and advances in the research and development of AAV‐based gene therapy to deliver large transgenes

Noninvasive, neuron-specific gene therapy can be facilitated by focused ultrasound and recombinant adeno-associated virus

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variants

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Optimized AAV capsids for diseases of the basal ganglia show robust potency and distribution in adult nonhuman primates

Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates

Delivery of Adeno-Associated Virus Vectors to the Central Nervous System for Correction of Single Gene Disorders

Taking the knife to neurodegeneration: a review of surgical gene therapy delivery to the CNS

A comprehensive review of AAV-mediated strategies targeting microglia for therapeutic intervention of neurodegenerative diseases

Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions